B-Cell Depletion by Immune Rosettes and B-Cell–Specific Magnetic Microbeads (CD19) of Leukaphereses Obtained From B-NHL, B-precursor ALL, or MM Patients
| Antibody Used . | B-NHL, B-precursor ALL and MM (n = 17) . | ||
|---|---|---|---|
| Apheresis (—) . | Immune Rosettes (CD11b) . | D-column (CD19*) . | |
| Total cell (×109) | 19.4 (8.6-41.4) | 2.4 (1.1-4.4) | 2 (0.9-3.6) |
| % overall cell loss | 85 (52-97) | 87 (59-98) | |
| CD34+cells (×109) | 0.3 (0.07-1.3) | 0.3 (0.06-1) | 0.2 (0.05-1) |
| %CD34+ cells | 1.8 (0.6-5.4) | 12 (1.5-28) | 14 (1.5-37) |
| %CD34 recovery | 85 (53-100) | 80 (48-100) | |
| %CD34 enrichment fold | 9 (2-35) | 10 (2-42) | |
| CD11b+cells (×109) | 15 (3.1-39.6) | 0.4 (0.01-1.2) | 0.2 (0.005-0.9) |
| %CD11b+ cells | 72 (37-98) | 19 (0.6-38) | 11 (0.4-28) |
| %CD11b+ cell loss | 96 (83-100) | 97 (87-100) | |
| CD3+ cells (×109) | 3.3 (0.5-8.4) | 1.4 (0.4-3) | 1.3 (0.4-2.6) |
| %CD3+ cells | 22 (1.4-55) | 58 (34-90) | 62 (42-92) |
| %CD3+ cell loss | 48 (11-78) | 52 (16-79) | |
| CD19+cells (×109) | 0.06 (0-0.2) | 0.02 (0-0.09) | 0.0004 (0-0.004) |
| %CD19+ cells | 0.4 (0-2) | 0.6 (0-2.3) | 0.02 (0-0.1) |
| %CD19+ cell loss | 72 (2.2-97) | 99 (94-100) | |
| Antibody Used . | B-NHL, B-precursor ALL and MM (n = 17) . | ||
|---|---|---|---|
| Apheresis (—) . | Immune Rosettes (CD11b) . | D-column (CD19*) . | |
| Total cell (×109) | 19.4 (8.6-41.4) | 2.4 (1.1-4.4) | 2 (0.9-3.6) |
| % overall cell loss | 85 (52-97) | 87 (59-98) | |
| CD34+cells (×109) | 0.3 (0.07-1.3) | 0.3 (0.06-1) | 0.2 (0.05-1) |
| %CD34+ cells | 1.8 (0.6-5.4) | 12 (1.5-28) | 14 (1.5-37) |
| %CD34 recovery | 85 (53-100) | 80 (48-100) | |
| %CD34 enrichment fold | 9 (2-35) | 10 (2-42) | |
| CD11b+cells (×109) | 15 (3.1-39.6) | 0.4 (0.01-1.2) | 0.2 (0.005-0.9) |
| %CD11b+ cells | 72 (37-98) | 19 (0.6-38) | 11 (0.4-28) |
| %CD11b+ cell loss | 96 (83-100) | 97 (87-100) | |
| CD3+ cells (×109) | 3.3 (0.5-8.4) | 1.4 (0.4-3) | 1.3 (0.4-2.6) |
| %CD3+ cells | 22 (1.4-55) | 58 (34-90) | 62 (42-92) |
| %CD3+ cell loss | 48 (11-78) | 52 (16-79) | |
| CD19+cells (×109) | 0.06 (0-0.2) | 0.02 (0-0.09) | 0.0004 (0-0.004) |
| %CD19+ cells | 0.4 (0-2) | 0.6 (0-2.3) | 0.02 (0-0.1) |
| %CD19+ cell loss | 72 (2.2-97) | 99 (94-100) | |
*In two MM patients purging experiments were performed by using anti-CD19 and anti-CD56 magnetic microbeads.